Molecular Imaging and Molecular Imaging Technologies

Molecular imaging has become an integral component of modern medicine. Defined by the molecular imaging center of excellence as “the visualization, characterization, and measurement of biological processes at the cellular and molecular level in humans and other living systems”, molecular imaging includes two- or three-dimensional noninvasive imaging as well as the quantification of acquired data over time [1]. Clinically, the importance of molecular imaging is paramount in the study and noninvasive diagnosis of diseases—based on molecular signatures rather than anatomic alterations—which in turn enables early detection of abnormalities and evaluation of new treatment approaches for improved survival rates. James and Gambhir summarized the main advantages of molecular imaging approaches: the possibility of studying cells in their natural environment without any disturbance from outside, the analysis of complex biological processes in real time, the investigation of signaling pathways in vivo, the gaining of information about drug delivery and pharmacokinetics, and the obtaining of multiple data sets in adequate resolution from the same patient over time [2].

[1]  N. Dowson,et al.  Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. , 2015, Seminars in nuclear medicine.

[2]  S. Groshen,et al.  Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. , 2014, American journal of nuclear medicine and molecular imaging.

[3]  H. Herzog,et al.  SPECT studies of brain tumors with L-3-[123I] iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Sanjiv S Gambhir,et al.  A molecular imaging primer: modalities, imaging agents, and applications. , 2012, Physiological reviews.

[5]  Sven N Reske,et al.  3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.

[6]  S S Gambhir,et al.  Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  S. Venneti,et al.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine , 2016, Nature Reviews Clinical Oncology.

[8]  D. Podoloff,et al.  The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[10]  Gerald Antoch,et al.  False-Positive FDG PET Uptake−the Role of PET/CT , 2006, European Radiology.

[11]  M. Fjällskog,et al.  Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors , 2003, Medical oncology.

[12]  M. P. Buchin,et al.  Performance Parameters of a Positron Imaging Camera , 1976, IEEE Transactions on Nuclear Science.

[13]  J. Kotzerke,et al.  18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Sameer Bansilal,et al.  Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.

[15]  Chun Li,et al.  Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. , 2003, Cancer research.

[16]  W. D. Mcelroy,et al.  Crystalline firefly luciferase. , 1956, Biochimica et biophysica acta.

[17]  Anna M. Wu,et al.  Antibodies and Antimatter: The Resurgence of Immuno-PET , 2008, Journal of Nuclear Medicine.

[18]  R. Boellaard,et al.  18F-FDG PET as a Tool to Predict the Clinical Outcome of Infliximab Treatment of Rheumatoid Arthritis: An Explorative Study , 2011, The Journal of Nuclear Medicine.

[19]  David M. Wilson,et al.  Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization. , 2014, Chemical Society reviews.

[20]  R. Miralbell,et al.  Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  S. Schulz,et al.  Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  Xiaoyuan Chen,et al.  Design and development of molecular imaging probes. , 2010, Current topics in medicinal chemistry.

[23]  E E de Lange,et al.  MR imaging and spectroscopy using hyperpolarized 129Xe gas: Preliminary human results , 1997, Magnetic resonance in medicine.

[24]  A. Nunn,et al.  Can receptors be imaged with MRI agents? , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[25]  Hua Ai,et al.  Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications. , 2014, Current opinion in pharmacology.

[26]  S. Lapi,et al.  Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use , 2013, The Journal of Nuclear Medicine.

[27]  À. Rovira,et al.  Proton MR Spectroscopy Improves Discrimination between Tumor and Pseudotumoral Lesion in Solid Brain Masses , 2009, American Journal of Neuroradiology.

[28]  F. Stuart Foster,et al.  Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis , 2007, Molecular imaging.

[29]  H. Stephan,et al.  Nuclear and optical dual-labelled imaging agents , 2016, Nuklearmedizin.

[30]  Mitchel S Berger,et al.  A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. , 2016, Journal of neurosurgery.

[31]  A. Nechansky HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. , 2010, Journal of pharmaceutical and biomedical analysis.

[32]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[33]  David W Townsend,et al.  PET/CT today and tomorrow. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  S. Srivastava,et al.  Technetium-99m: an historical perspective. , 1982, The International journal of applied radiation and isotopes.

[35]  A. Alavi,et al.  Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  Cassius Vinicius Stevani,et al.  Firefly Luminescence: a Historical Perspective and Recent Developments the Structural Origin and Biological Function of Ph-sensitivity in Firefly Luciferases Activity Coupling and Complex Formation between Bacterial Luciferase and Flavin Reductases Coelenterazine-binding Protein of Renilla Muelleri: , 2022 .

[37]  E. R. Andrew Nuclear magnetic resonance and the brain , 2005, Brain Topography.

[38]  I. Donald,et al.  Investigation of abdominal masses by pulsed ultrasound. , 1958, Lancet.

[39]  Jan Grimm,et al.  Cerenkov imaging. , 2014, Advances in cancer research.

[40]  P. Blower,et al.  Hypoxia imaging with PET: which tracers and why? , 2012, Nuclear medicine communications.

[41]  S. Batra,et al.  Recent trends in antibody-based oncologic imaging. , 2012, Cancer letters.

[42]  Erlong Zhang,et al.  A review of NIR dyes in cancer targeting and imaging. , 2011, Biomaterials.

[43]  Zhigang Wang,et al.  Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[44]  S. Meikle,et al.  Small animal SPECT and its place in the matrix of molecular imaging technologies , 2005, Physics in medicine and biology.

[45]  P. Kuo Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. , 2008, Journal of the American College of Radiology : JACR.

[46]  D. Vriens,et al.  Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review , 2009, Journal of Nuclear Medicine.

[47]  R. Bradley,et al.  A review of attenuation correction techniques for tissue fluorescence , 2006, Journal of The Royal Society Interface.

[48]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[49]  Byung-Tae Kim,et al.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. , 2005, Radiology.

[50]  J. Vercher-Conejero,et al.  Clinical oncologic applications of PET/MRI: a new horizon. , 2014, American journal of nuclear medicine and molecular imaging.

[51]  S. Ramin,et al.  Application of 11C‐acetate positron‐emission tomography (PET) imaging in prostate cancer: systematic review and meta‐analysis of the literature , 2013, BJU international.

[52]  Ulrich B Wiesner,et al.  Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[53]  H. Dittmann,et al.  [18F]FLT PET for diagnosis and staging of thoracic tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  M. Thaning,et al.  Real-time metabolic imaging. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Y. Akagi,et al.  Navigation surgery for intraoperative sentinel lymph node detection using Indocyanine green (ICG) fluorescence real-time imaging in breast cancer , 2015, Breast Cancer Research and Treatment.

[56]  David A. Mankoff,et al.  PET/CT imaging in cancer: Current applications and future directions , 2014, Cancer.

[57]  Ora Israel,et al.  Cancer Recurrence: Diagnostic Value and Impact on Patient Management , 2004 .

[58]  H. Steinert,et al.  Single-photon emission computed tomography/computed tomographyfor sentinel node mapping in breast cancer. , 2007, Seminars in nuclear medicine.

[59]  Sarah E Bohndiek,et al.  Contrast agents for molecular photoacoustic imaging , 2016, Nature Methods.

[60]  P. Lauterbur,et al.  Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance , 1973, Nature.

[61]  M. Frydenberg,et al.  Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice , 2002, Acta oncologica.

[62]  W. Oyen,et al.  Radiolabelled peptides for oncological diagnosis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  Joong-Won Park,et al.  [Diagnostic accuracy of 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma]. , 2006, The Korean journal of hepatology.

[64]  P. Larson,et al.  Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.

[65]  Joshua S Richman,et al.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer , 2015, Clinical Cancer Research.

[66]  L. Kemna,et al.  Iodine-123 α-methyl tyrosine single-photon emission tomography of cerebral gliomas: standardised evaluation of tumour uptake and extent , 1998, European Journal of Nuclear Medicine.

[67]  M. Ferrari,et al.  18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  J S Petersson,et al.  Molecular imaging using hyperpolarized 13C. , 2003, The British journal of radiology.

[69]  U. Haberkorn,et al.  [18F]FLT; portrait of a proliferation marker. , 2002, European journal of nuclear medicine and molecular imaging.

[70]  R. Clarkson Blood-Pool MRI Contrast Agents: Properties and Characterization , 2002 .

[71]  S. Singhal,et al.  Identification of breast cancer margins using intraoperative near‐infrared imaging , 2016, Journal of surgical oncology.

[72]  M. Muzi,et al.  Applications of PET imaging with the proliferation marker [18F]-FLT. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[73]  A. Drzezga,et al.  First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.

[74]  O. Shimomura,et al.  Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. , 1962, Journal of cellular and comparative physiology.

[75]  Yun Sun,et al.  Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles. , 2011, Biomaterials.

[76]  H. Groen,et al.  Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  A. Scarsbrook,et al.  The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. , 2008, Clinical radiology.

[78]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[79]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[80]  E. Sorantin,et al.  Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging , 2008, Nuklearmedizin.

[81]  Jonathan M. Links,et al.  Imaging dopamine receptors in the human brain by positron tomography , 1983 .

[82]  Sarah E Bohndiek,et al.  Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors , 2009, Proceedings of the National Academy of Sciences.

[83]  A. Alavi,et al.  Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose. , 1977, Acta neurologica Scandinavica. Supplementum.

[84]  M. Renz Fluorescence microscopy—A historical and technical perspective , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[85]  W. Schima,et al.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications , 2004, European Radiology.

[86]  S R Cherry,et al.  Optical imaging of Cerenkov light generation from positron-emitting radiotracers , 2009, Physics in medicine and biology.

[87]  W. Moses Fundamental Limits of Spatial Resolution in PET. , 2011, Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment.

[88]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[89]  V. Grégoire,et al.  A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[91]  A. Grichine,et al.  Reply to: Comments on 'Intraoperative near-infrared fluorescence imaging using indocyanine green in colorectal carcinomatosis surgery: Proof of concept'. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[92]  Jan Henrik Ardenkjaer-Larsen,et al.  Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. , 2006, Cancer research.

[93]  Wolfgang A. Weber,et al.  O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.

[94]  Monique R Bernsen,et al.  Computed tomography and magnetic resonance imaging. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[95]  E. Krenning,et al.  (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. , 2011, Seminars in nuclear medicine.

[96]  P. Metellus,et al.  5-Aminolevulinic Acid-Protoporphyrin IX Fluorescence-Guided Surgery of High-Grade Gliomas: A Systematic Review. , 2016, Advances and technical standards in neurosurgery.

[97]  M Goldsmith,et al.  NMR in cancer: XVI. FONAR image of the live human body. , 1977, Physiological chemistry and physics.

[98]  Minyong Li,et al.  Cage the firefly luciferin! - a strategy for developing bioluminescent probes. , 2013, Chemical Society reviews.

[99]  M P Sandler,et al.  FDG-SPECT: correlation with FDG-PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[100]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  Cristina Martelli,et al.  Optical imaging probes in oncology , 2016, Oncotarget.

[102]  Jan Grimm,et al.  Clinical Cerenkov Luminescence Imaging of 18F-FDG , 2014, The Journal of Nuclear Medicine.

[103]  M S Rosenthal,et al.  Quantitative SPECT imaging: a review and recommendations by the Focus Committee of the Society of Nuclear Medicine Computer and Instrumentation Council. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  Yi-Xiang J. Wang Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. , 2011, Quantitative imaging in medicine and surgery.

[105]  M. Blaufox,et al.  A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases , 2005, Breast Cancer Research and Treatment.

[106]  R. Weissleder,et al.  Molecular imaging of gene therapy for cancer , 2004, Gene Therapy.

[107]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[108]  J. Mukherjee,et al.  11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas , 2007, Molecular Imaging and Biology.

[109]  J. Pinski,et al.  FDG PET in suspected recurrent and metastatic prostate cancer. , 2003, Oncology reports.

[110]  H. Jun,et al.  Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model. , 2010, Academic radiology.

[111]  A. Grichine,et al.  Intraoperative Near-Infrared Fluorescence Imaging using indocyanine green in colorectal carcinomatosis surgery: Proof of concept. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[112]  L. Jeng,et al.  18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. , 2012, European journal of radiology.

[113]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[114]  T. Etrych,et al.  Fluorescence optical imaging in anticancer drug delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[115]  Greg M. Thurber,et al.  Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.

[116]  Jan Wolber,et al.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy , 2007, Nature Medicine.

[117]  R. Wahl,et al.  Initial experience with FDG-PET/CT in the evaluation of breast cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[118]  S. Vallabhajosula Molecular Imaging: Radiopharmaceuticals for PET and SPECT , 2009 .

[119]  A. Alavi,et al.  FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[120]  Christos Davatzikos,et al.  Imaging genomics in cancer research: limitations and promises. , 2016, The British journal of radiology.

[121]  W. Edelstein,et al.  The intrinsic signal‐to‐noise ratio in NMR imaging , 1986, Magnetic resonance in medicine.

[122]  J. Moretti,et al.  Clinical validation of simultaneous dual-isotope myocardial scintigraphy , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[123]  Zhi-Yi Chen,et al.  Targeted gene delivery in tumor xenografts by the combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit survivin gene expression and induce apoptosis , 2010, Journal of experimental & clinical cancer research : CR.

[124]  Paul M. Parizel,et al.  Clinical MR imaging , 1999 .

[125]  I. Nöbauer-Huhmann,et al.  The optimal use of contrast agents at high field MRI , 2006, European Radiology.

[126]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[127]  Konstantin Nikolaou,et al.  25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives , 2016, Advances in Therapy.

[128]  G. Chiro Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .

[129]  R. Weissleder,et al.  Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. , 2012, Neoplasia.

[130]  W. Oyen,et al.  Fluorinated amino acids for tumour imaging with positron emission tomography , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[131]  K. Kubota,et al.  Whole-body FDG-PET/CT on rheumatoid arthritis of large joints , 2009, Annals of nuclear medicine.

[132]  W. Oyen,et al.  PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[133]  Robert A. deKemp,et al.  The Use of 18F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience , 2012, The Journal of Nuclear Medicine.

[134]  Young‐Tae Chang,et al.  A macrophage-specific fluorescent probe for intraoperative lymph node staging. , 2014, Cancer research.

[135]  Jan Grimm,et al.  Positron Lymphography: Multimodal, High-Resolution, Dynamic Mapping and Resection of Lymph Nodes After Intradermal Injection of 18F-FDG , 2012, The Journal of Nuclear Medicine.

[136]  C. Claussen,et al.  Evaluation of combined transmission and emission tomography for classification of skeletal lesions. , 2004, AJR. American journal of roentgenology.

[137]  E. Chekmenev,et al.  Low-field MRI can be more sensitive than high-field MRI. , 2013, Journal of magnetic resonance.

[138]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[139]  G. V. van Dongen,et al.  The promise of immuno-PET in radioimmunotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[140]  Johannes A Langendijk,et al.  PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III–IV Non–Small Cell Lung Cancer Patients , 2013, The Journal of Nuclear Medicine.

[141]  R. Hustinx,et al.  Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[142]  E. Krenning,et al.  Somatostatin receptor imaging. , 2002, Seminars in nuclear medicine.

[143]  H. Weinmann,et al.  First use of GdDTPA/dimeglumine in man. , 1984, Physiological chemistry and physics and medical NMR.

[144]  F Dehdashti,et al.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[145]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[146]  Thomas Beyer,et al.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  Carlo Cavedon,et al.  First human Cerenkography , 2013, Journal of biomedical optics.

[148]  E. Krenning,et al.  Somatostatin receptor imaging for neuroendocrine tumors , 2006, Pituitary.

[149]  Judit Erchegyi,et al.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.

[150]  Jan Grimm,et al.  Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions , 2011, Molecular imaging.

[151]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[152]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[153]  F. Korosec,et al.  Functional lung imaging using hyperpolarized gas MRI , 2007, Journal of magnetic resonance imaging : JMRI.

[154]  J. Kurhanewicz,et al.  Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. , 2013, Cancer research.

[155]  S. Larson,et al.  Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. , 2010, Gynecologic oncology.

[156]  E. Even-Sapir Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[157]  Michael Sabel,et al.  Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[158]  Dale L. Bailey,et al.  Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[159]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[160]  D. Matchar,et al.  FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.

[161]  S. Schoenberg,et al.  High-Resolution Whole-Body Magnetic Resonance Image Tumor Staging With the Use of Parallel Imaging Versus Dual-Modality Positron Emission Tomography–Computed Tomography: Experience on a 32-Channel System , 2005, Investigative radiology.

[162]  Gerald Reischl,et al.  PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[163]  J. M. Udias,et al.  Simulation of triple coincidences in PET , 2013, 2013 IEEE Nuclear Science Symposium and Medical Imaging Conference (2013 NSS/MIC).

[164]  V. Ntziachristos Fluorescence molecular imaging. , 2006, Annual review of biomedical engineering.

[165]  Aaron M Mohs,et al.  Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential , 2007, Expert opinion on drug delivery.

[166]  Fabian Kiessling,et al.  Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery , 2015, Front. Pharmacol..

[167]  Marie-France Bellin,et al.  Extracellular gadolinium-based contrast media: an overview. , 2008, European journal of radiology.

[168]  Massoud Motamedi,et al.  Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[169]  Ciprian Catana,et al.  Simultaneous PET-MRI: a new approach for functional and morphological imaging , 2008, Nature Medicine.

[170]  G. Moore,et al.  The clinical use of fluorescein in neurosurgery; the localization of brain tumors. , 1948, Journal of neurosurgery.

[171]  A. Constantinesco,et al.  18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[172]  Sam SIDDIGHI,et al.  Indocyanine green for intraoperative localization of ureter. , 2014, American journal of obstetrics and gynecology.

[173]  Sven Perner,et al.  Imaging prostate cancer with 11C-choline PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[174]  G. Denardo,et al.  Trials and tribulations: oncological antibody imaging comes to the fore. , 1997, Seminars in nuclear medicine.

[175]  K Kubota,et al.  From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology , 2001, Annals of nuclear medicine.

[176]  Jennifer A. Prescher,et al.  Bioluminescence: a versatile technique for imaging cellular and molecular features. , 2014, MedChemComm.

[177]  Eduardo Schiffer,et al.  Intra‐operative fluorescent cholangiography using indocyanin green during robotic single site cholecystectomy , 2012, The international journal of medical robotics + computer assisted surgery : MRCAS.

[178]  Wolfgang A Weber,et al.  An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. , 2011, International journal of radiation oncology, biology, physics.

[179]  M. Reiser,et al.  Whole-body MRI for the staging and follow-up of patients with metastasis. , 2009, European journal of radiology.

[180]  L. Bachmann,et al.  The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. , 2013, European urology.

[181]  G. Treglia,et al.  Usefulness of 11C-Methionine Positron Emission Tomography in Differential Diagnosis between Recurrent Tumours and Radiation Necro-sis in Patients with Glioma: An Overview , 2012 .

[182]  M. Shibutani,et al.  Preferential tumor cellular uptake and retention of indocyanine green for in vivo tumor imaging , 2016, International journal of cancer.

[183]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[184]  Jan Grimm,et al.  Cerenkov Luminescence Imaging of Medical Isotopes , 2010, Journal of Nuclear Medicine.

[185]  H. Carmalt,et al.  SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. , 2012, Breast.

[186]  R. Weissleder,et al.  In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. , 2004, Arthritis and rheumatism.

[187]  S S Gambhir,et al.  A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[188]  E. Krenning,et al.  Octreoscan radioreceptor imaging , 2003, Endocrine.

[189]  J. Mansfield,et al.  Distinguished photons: a review of in vivo spectral fluorescence imaging in small animals. , 2010, Current pharmaceutical biotechnology.

[190]  David A Mankoff,et al.  A definition of molecular imaging. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[191]  R. Jones,et al.  Immunological Properties of an Antibody Containing a Fluorescent Group.∗ , 1941 .

[192]  R. Q. Edwards,et al.  The Mark IV system for radionuclide computed tomography of the brain. , 1976, Radiology.

[193]  R. Boellaard Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[194]  Boyd M. Goodson Nuclear magnetic resonance of laser-polarized noble gases in molecules, materials, and organisms. , 2002 .

[195]  Jonathan F. Lovell,et al.  Porphyrins as Theranostic Agents from Prehistoric to Modern Times , 2012, Theranostics.

[196]  A. D’Amico,et al.  A Brief History of Active Sonar , 2009 .

[197]  K Kirk Shung,et al.  High Frequency Ultrasonic Imaging. , 2009, Journal of medical ultrasound.

[198]  R Weissleder,et al.  Near-infrared optical imaging of protease activity for tumor detection. , 1999, Radiology.

[199]  Bruce D Cheson,et al.  Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.

[200]  Arion F. Chatziioannou,et al.  Molecular imaging of small animals with dedicated PET tomographs , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[201]  Graham M. Treece,et al.  Three-dimensional ultrasound imaging , 2010, Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine.

[202]  Samuel Achilefu,et al.  Optical Imaging in Cancer Research: Basic Principles, Tumor Detection, and Therapeutic Monitoring , 2011, Medical Principles and Practice.

[203]  Barry H. Smith,et al.  18F-2-FLUORO-2-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY OF HUMAN CEREBRAL GLIOMAS , 1981 .

[204]  Rajiv Gupta,et al.  Advances in computed tomography imaging technology. , 2014, Annual review of biomedical engineering.

[205]  Kevin M Brindle,et al.  Imaging tumour cell metabolism using hyperpolarized 13C magnetic resonance spectroscopy. , 2010, Biochemical Society transactions.

[206]  D. Patton The birth of nuclear medicine instrumentation: Blumgart and Yens, 1925. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[207]  M. Nicolson,et al.  Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer , 1998, The British journal of surgery.

[208]  Yajing Liu,et al.  Photoacoustic Molecular Imaging: From Multiscale Biomedical Applications Towards Early-Stage Theranostics. , 2016, Trends in biotechnology.

[209]  F. Kiessling,et al.  Targeted ultrasound imaging of cancer: an emerging technology on its way to clinics. , 2012, Current pharmaceutical design.

[210]  Douglas A Levine,et al.  Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. , 2014, Gynecologic oncology.

[211]  Joaquin L. Herraiz,et al.  Recovery and normalization of triple coincidences in PET. , 2015, Medical physics.

[212]  Ludwig G. Strauss,et al.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.

[213]  Y. Dohi,et al.  Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. , 2004, Chest.

[214]  M. Albert,et al.  Development of hyperpolarized noble gas MRI. , 1998, Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment.

[215]  J. Capala,et al.  The role of nuclear medicine in modern therapy of cancer , 2012, Tumor Biology.

[216]  Thomas Beyer,et al.  Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[217]  Tingting Xu,et al.  In Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living Animals , 2010, Sensors.

[218]  Leif Østergaard,et al.  Final infarct size after acute stroke: prediction with flow heterogeneity. , 2002, Radiology.

[219]  N. Sadato,et al.  11C-acetate PET imaging of prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[220]  M. Reivich,et al.  Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose , 1978 .

[221]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[222]  J. Reubi,et al.  Peptide-Based Probes for Cancer Imaging , 2008, Journal of Nuclear Medicine.

[223]  A. Drzezga,et al.  Current status and future role of brain PET/MRI in clinical and research settings , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[224]  P. Curie,et al.  Développement par compression de l'électricité polaire dans les cristaux hémièdres à faces inclinées , 1880 .

[225]  Stefano Fanti,et al.  The clinical use of PET with (11)C-acetate. , 2012, American journal of nuclear medicine and molecular imaging.

[226]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[227]  Wolfgang Uter,et al.  In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease , 2014, Nature Medicine.

[228]  A. Alavi,et al.  The [18F]Fluorodeoxyglucose Method for the Measurement of Local Cerebral Glucose Utilization in Mane , 1979, Circulation research.

[229]  Thomas C. Kwee,et al.  Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis , 2008, European Radiology.

[230]  Y. Yonekura,et al.  A strategy for the study of cerebral amino acid transport using iodine-123-labeled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-L-tyrosine. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[231]  H C Charles,et al.  Human lung air spaces: potential for MR imaging with hyperpolarized He-3. , 1996, Radiology.

[232]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[233]  Sanjiv S Gambhir,et al.  Reporter gene imaging of protein-protein interactions in living subjects. , 2007, Current opinion in biotechnology.

[234]  K. Chuang,et al.  Magnetic resonance imaging (MRI) contrast agents for tumor diagnosis. , 2013, Journal of healthcare engineering.

[235]  G. Radda,et al.  Molecular imaging perspectives , 2005, Journal of The Royal Society Interface.

[236]  Thomas E Yankeelov,et al.  MR Imaging Biomarkers in Oncology Clinical Trials. , 2016, Magnetic resonance imaging clinics of North America.

[237]  E. Krenning,et al.  Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results , 2017, The Journal of Nuclear Medicine.

[238]  E. N. Harvey,et al.  A History of Luminescence: From the Earliest Times Until 1900 , 2005 .

[239]  M. Khalil,et al.  Molecular SPECT Imaging: An Overview , 2011, International journal of molecular imaging.

[240]  Jochen Herms,et al.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[241]  R. Schibli,et al.  Versatile routes to C-2- and C-6-functionalized glucose derivatives of iminodiacetic acid. , 2003, The Journal of organic chemistry.

[242]  W. Schultze‐Seemann,et al.  GRPR antagonist 68Ga-RM2 as PET tracer for imaging prostate cancer: Initial experiences , 2014 .

[243]  T. Budinger,et al.  NMR of laser-polarized xenon in human blood. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[244]  Siavash Yazdanfar,et al.  Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met , 2015, Nature Medicine.

[245]  R Myers,et al.  The biological application of small animal PET imaging. , 2001, Nuclear medicine and biology.

[246]  Vasilis Ntziachristos,et al.  Advancing Surgical Vision with Fluorescence Imaging. , 2016, Annual review of medicine.

[247]  D. Kacher,et al.  Hyperpolarized 129Xe MR imaging of the oral cavity. , 1996, Journal of magnetic resonance. Series B.

[248]  Jorge Ripoll,et al.  Advances in optical imaging for pharmacological studies , 2015, Front. Pharmacol..

[249]  A. Rosato,et al.  Optical and multimodal peptide-based probes for in vivo molecular imaging. , 2012, Anti-cancer agents in medicinal chemistry.

[250]  S. -O. Bohman,et al.  GLOMERULAR CRESCENT CELLS , 1976, The Lancet.

[251]  S. Lamberts,et al.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. , 2003, Endocrine-related cancer.

[252]  Jianlin Yuan,et al.  Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field , 2014, International journal of nanomedicine.

[253]  V. Ntziachristos,et al.  Molecular imaging by means of multispectral optoacoustic tomography (MSOT). , 2010, Chemical reviews.

[254]  E. Hoffman,et al.  A positron-emission transaxial tomograph for nuclear imaging (PETT). , 1975, Radiology.

[255]  Ralph Weissleder,et al.  Near-infrared optical imaging of proteases in cancer. , 2003, Molecular cancer therapeutics.

[256]  L. Sorensen,et al.  VISUALIZATION OF THE LIVER BY SCANNING WITH MO99 (MOLYBDATE) AS TRACER. , 1963, The Journal of laboratory and clinical medicine.

[257]  Yin Zhang,et al.  PET tracers based on Zirconium-89. , 2011, Current radiopharmaceuticals.

[258]  D W Townsend,et al.  Physical principles and technology of clinical PET imaging. , 2004, Annals of the Academy of Medicine, Singapore.

[259]  J. Mehrkens,et al.  The positive predictive value of O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment , 2008, Journal of Neuro-Oncology.

[260]  M. Neurath,et al.  Endomicroscopic Imaging of COX-2 Activity in Murine Sporadic and Colitis-Associated Colorectal Cancer , 2013, Diagnostic and therapeutic endoscopy.